DMT Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 31.08%

Insider Buying (Last 12 Months): C$0.00

Insider Selling (Last 12 Months): C$43,511.60

Small Pharma Insider Trading History Chart

Small Pharma Share Price & Price History

C^$0.15

▼ -0.01 (-6.25%)

As of 10/21/2023 12:59 AM ET

Days: 30 | 90 | 365

Exposed: 10 CENT Crypto to Explode April 20th?

From True Market Insiders | Ad

The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

Click For My #1 FREE Crypto for 2024

Small Pharma Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/25/2023	Peter David Rands	Insider	Sell	638,000	C$0.07	C$43,511.60
10/27/2022	Peter David Rands	Director	Sell	60,000	C$0.17	C$10,200.00	9,103,450
8/31/2022	Peter David Rands	Director	Buy	5,000	C$0.27	C$1,325.00	78,275,443
8/29/2022	Peter David Rands	Director	Buy	25,000	C$0.20	C$5,000.00	78,176,943
8/26/2022	Peter David Rands	Director	Buy	2,500	C$0.20	C$487.50	78,014,943
8/19/2022	Peter David Rands	Director	Buy	2,500	C$0.20	C$487.50	77,589,333
7/27/2022	Peter David Rands	Director	Buy	117,000	C$0.13	C$15,210.00	77,586,833
7/20/2022	Michael Andrew Wolfe	Director	Buy	40,000	C$0.10	C$3,800.00	100,000

These AI trades triggered this morning (545% return)

From Prosper Trading Academy | Ad

If you think a market crash is possible in 2024, I don't know why you're not using this yet.

Click Here To Get Your Free Copy

SEC Filings (Institutional Ownership Changes) for Small Pharma (CVE:DMT)

0.67% of Small Pharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Small Pharma Inc., a biotechnology company, focuses on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions. Its clinical program is based on N,N, dimethyltryptamine, a naturally occurring psychoactive molecule. The company's product includes SPL026, which is in clinical Phase IIa for the treatment of major depressive disorder; and SPL028, an injectable formulation of deuterated DMT, which is in Phase 1 clinical trial, as well as SPL801B, an oral dosage. Its preclinical stage programs include SPL029, an oral formulation of a tryptamine to treat depressive disorder. The company is headquartered in London, the United Kingdom. As of October 23, 2023, Small Pharma Inc. operates as a subsidiary of Cybin Inc.

Today's Range

Now: C$0.15

C$0.15

C$0.16

50 Day Range

MA: C$0.15

C$0.15

52 Week Range

Now: C$0.15

C$0.06

C$0.22

Volume

1,890,765 shs

Average Volume

296,159 shs

Market Capitalization

C$50.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Who are the company insiders with the largest holdings of Small Pharma?: Small Pharma's top insider investors include:
Peter David Rands (Director)
Michael Andrew Wolfe (Director)
Peter David Rands (Insider)
Learn More about top insider investors at Small Pharma.